fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Cefoxitin sodium

All injection strengths: not a benefit

Mefoxin · DIN 00663700 · 2 g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.Discontinued July 29, 2002 · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Mefoxin · DIN 00663700 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 2008-06-27 Health Canada: Cancelled post market since 2002-07-29 · brand MEFOXIN PWS 2GM/VIAL · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFOXITIN (CEFOXITIN SODIUM) 2 G/VIAL · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mefoxin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00663700)

Source record
DIN 00663700: Mefoxin Raw flags: sec3=Y, sec3b=Y Item: 081228120; group id 39; item number 0080; lccId None; manufacturer id MSD Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00663700 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8164
Interchangeable products
Cefoxitin for Injection · DIN 02291738 · $21.2500 Cefoxitin for Injection USP · DIN 02128195 · $21.2500
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since July 29, 2002 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01D, J01DC): coverage varies; not interchangeable

  • Cefprozil (Ran-Cefprozil): general benefit, not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, not a benefit
  • Cefadroxil (Duricef): general benefit, not a benefit
  • Cefixime (Suprax): general benefit
  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cephalexin (Ceporex): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bone and joint infections, gynecological infections, intra-abdominal infections, lower respiratory tract infections, septicemia, urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Urinary tract infections (complicated and uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Listed, not a benefit (1) • Gynecological infections including endometritis, pelvic cellulitis, vaginal cuff infections, non-gonococcal tubo-ovarian abscess, salpingitis, and pelvic inflammatory disease when caused by susceptible anaerobes or Chlamydia trachomatis. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Intra-abdominal infections including peritonitis and abdominal abscess when caused by susceptible anaerobes. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis) and susceptible anaerobes, where the bactericidal efficacy of clindamycin against the infecting organism has been determined in vitro at achievable serum levels. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Bone and joint infections including osteomyelitis and septic arthritis when caused by sensitive strains of Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph AMOXICILLIN & CLAVULANIC ACID · General benefit (22), Listed, not a benefit (3) • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. PM: https://pdf.hres.ca/dpd_pm/00084428.PDF; date 2026-04-24; DIN 01916874; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TREATMENT For the treatment of the following infections when due to susceptible organisms: 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess 2 - Gynecological infections such as endometritis and pelvic cellulitis 3 - Septicemia 4 - Urinary tract infections (including those caused by Serratia marcescens and Serratia spp.) 5 - Lower respiratory tract infections 6 - Bone and joint infections caused by Staphylococcus aureus 7 - Soft tissue infections such as cellulitis, abscesses and wound infections The susceptibility of the causative organism(s) to Cefoxitin for Injection should be determined by conducting appropriate culture and susceptibility studies. Therapy may be initiated while awaiting these test results. Adjustments in treatment may be required once these results become available. Organisms particularly appropriate for therapy with Cefoxitin for Injection are: Gram positive Staphylococci: penicillinase producing and non-producing Streptococci excluding enterococci Gram negative (beta-lactamase producing and non-producing strains) E. coli Klebsiella species (including K. pneumoniae)… https://pdf.hres.ca/dpd_pm/00073366.PDF PM date: November 16, 2023 Source product: CEFOXITIN FOR INJECTION; DIN 02128187; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Mefoxin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026